Merck + Co., Inc.

Jerrold M Liesch

Otto D Hensens

Robert E Schwartz

David F Sesin

Gerald F Bills

Janet C Onishi

Francisca Vicente

Carol F Wichmann

Fernando Pelaez

Robert A Giacobbe

Prakash S Masurekar

Deborah L Zink

Leeyuan Huang

Louis Kaplan

Sagrario M Del Val

Maria T Diez

Richard W Burg

Lawrence R Koupal

Sandra A Morris

Robert T Goegelman

Sebastian Hernandez

Henry Joshua

John R Thompson

Isabel Martin

John G Ondeyka

James E Curotto

Angela Basilio

Jimmy M Fountoulakis

Lucille J Cole

Wendy S Horn

Sarah J Dreikorn

Maria S Meinz

Angeles Cabello

James A Milligan

Rosalind G Jenkins

Michael J Salvatore, Jr

Isabella Martin

H Boyd Woodruff

Joseph Dunn, Jr

Thomas C Hallada

Roger M Freidinger

Richard L Monaghan

George M Garrity

Raymond F White

Dennis M Schmatz

Kenneth E Wilson

Paul S Anderson

Michael A Goetz

Douglas J Pettibone

Jon D Polishook

Eugene L Dulaney

Yu L Kong

James D Bergstrom

Jack L Smith

Kevin M Byrne

Cheryl D Schwartz

Michael D Greenspan

James E Flor

Gregory L Helms

Walter Rozdilsky

Frank L VanMiddlesworth

Myra B Kurtz

Richard K Jansson

Charles F Hirsch

Maria T Matas

E Tracy Turner Jones

Ruth S Sykes

Leeyan Huang

Susan L Raghoobar

Russel B Lingham

Teresa Diez

Reamer, Robert A

Robert A Fromtling

Elvira Munguira

Maria T Diez Matas

There are disclosed novel compounds having the formula ##STR1## which exhibit antifungal activity.

Antifungal agents

There is disclosed a novel compound having the formula ##STR1## which exhibits antifungal activity.

Antifungal agent obtained from hormonema

There is disclosed a compound having the formula ##STR1## which is produced by the fungus, Arthrinium arundinis ATCC 74359, and exhibits antifungal activity.

Antifungal agent produced by arthrinium arundinis  ATCC 74359

Novel peptidyl derivatives of formula I are found to be potent inhibitors of interleukin-1.beta. converting enzyme (ICE). Compounds of formula I may be useful in the treatment of inflammatory or immune-based diseases of the lung and airways; central nervous system and surrounding membranes; the eyes and ears; joints, bones, and connective tissues; cardiovascular system including the pericardium; the gastrointestinal and urogenital systems; the skin and mucosal membranes. Compounds of formula I are also useful in treating the complications of infection (e.g., gram negative shock) and tumors in which IL 1 functions as an autocrine growth factor or as a mediator of cachexia. ##STR1##

Gamma-pyrone-3-acetic acid as an inhibitor or interleukin-1 .beta.

A new antibiotic cyclic lipopeptide having the formula ##STR1## wherein R is H or OH and a method of producing is described. The agent has very high activity against human pathogens and is of very low mammalian toxicity.

Antibiotic agent

A new antibiotic cyclic lipopeptide having the formula ##STR1## wherein R is H SEQ ID NO:1 or OH SEQ ID NO:2 and a method of producing is described. The agent has very high activity against human pathogens and is of very low mammalian toxicity.

There is disclosed a series of macrolides isolated from the fermentation broth of microorganisms identified as MA-6825, MA-6864 and MA-6865. The structure of the novel compounds isolated from the microorganisms is presented based upon analytical studies. The compounds are highly potent antiparasitic, insecticidal, and anthelmintic agents and are related to the class of macrolides known as milbemycins. Compositions for such uses are also disclosed.

Anthelmintic milbemycin analogs of novel microorganisms

New antibiotic eicosenoic acids and a method of producing it are described. The acids have been found to have antifungal properties.

Antibiotic eicosenoic acids

An antibiotic agent produced by the cultivation of Zalerion arboricola which is a cyclic lipopeptide with very high activity against human pathogens and of very low mammalian toxicity is described. Its production and isolation are also described.

Antibiotic cyclopeptide fermentation product

There is disclosed a series of macrolides isolated from the fermentation broth of a microorganism identified as MA-5000 which morphological analysis reveals to be a strain of Streptomyces hygroscopicus. The compounds structures are presented based upon analytical studies. The compounds have antifungal activity.

Antifungal substances and process for their production

This invention relates to compounds of structural formula (I): ##STR1## which are squalene synthetase inhibitors and thus useful as cholesterol lowering agents.

Novel squalene synthetase inhibitors

Cyclic peptides are produced by the controlled aerobic fermentation of Streptomyces silvensis, ATTCC No. 53525 or ATCC No. 53526. These compounds are antagonists of oxytocin and are useful in the treatment of preterm labor and vasopressin and are thus useful in the treatment and prevention of disease states wherein vasopressin may be involved, for example congestive heart failure, hypertension, edema and hyponatremia.

Oxytocin and vasopressin antagonists

Disclosed is a novel lipophilic macrolide of Formula I: ##STR1## The compound of assigned Formula I is an analog of rapamycin which has activity as an antifungal agent and as an immunosuppressant.

Lipophilic macrolide useful as an immunosuppressant

Disclosed is a novel lipophilic macrolide of assigned Formula I: ##STR1## The compound of assigned Formula I is an analog of rapamycin which has activity as an antifungal agent and as an immunosuppressant.

Growing community of inventors

Princeton Junction, NJ, United States of America

Jerrold M Liesch